KB Securities Has High Expectations for Yuhan Corporation's Leclaza
Recommends "Buy" Rating

[Click e-Stock] Yuhan Corporation Expected to See Full-Fledged Royalty Inflows... Target Price Set at 125,000 Won View original image

On May 28, KB Securities initiated coverage on Yuhan Corporation, giving it a "Buy" investment opinion and a target price of 125,000 won, stating that the company is expected to enter a phase where royalty inflows will be fully realized.


Jihoon Shin, an analyst at KB Securities, commented, "Yuhan Corporation is benefiting from several positive factors, including royalty inflows from the market entry of Lazcluze (the U.S. name for Leclaza), contract development and manufacturing organization (CDMO) orders at Yuhan Chemical, sales expansion driven by capacity increase, and the highlighted value of its pipeline."


Shin further explained, "Annual sales for Lazcluze are forecast to reach 4 billion dollars by 2030, which stems from its strong clinical superiority over the competing drug Tagrisso."



He added, "The new allergy drug Lesigercept demonstrated a stronger and more sustained immunoglobulin E (IgE) reduction effect compared to the blockbuster drug Xolair in the Phase 1b trial. In particular, it has drawn market expectations by confirming symptom improvement even among patients with chronic spontaneous urticaria (CSU) who do not respond to Xolair."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing